194 related articles for article (PubMed ID: 37504373)
1. Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study).
Comito T; Massaro M; Teriaca MA; Franzese C; Franceschini D; Navarria P; Clerici E; Di Cristina L; Bertolini A; Tomatis S; Reggiori G; Bresolin A; Bozzarelli S; Rimassa L; Bonifacio C; Carrara S; Santoro A; Zerbi A; Scorsetti M
Curr Oncol; 2023 Jul; 30(7):7073-7088. PubMed ID: 37504373
[TBL] [Abstract][Full Text] [Related]
2. Stereotactic body radiotherapy vs conventionally fractionated chemoradiation in locally advanced pancreatic cancer: A multicenter case-control study (PAULA-1).
Arcelli A; Buwenge M; Macchia G; Bertini F; Guido A; Deodato F; Cilla S; Scotti V; Rosetto ME; Djan I; Parisi S; Mattiucci GC; Cellini F; Fiore M; Bonomo P; Belgioia L; Niespolo RM; Gabriele P; Di Marco M; Simoni N; Mazzarotto R; Morganti AG;
Cancer Med; 2020 Nov; 9(21):7879-7887. PubMed ID: 32910549
[TBL] [Abstract][Full Text] [Related]
3. Linac-based stereotactic body radiation therapy for unresectable locally advanced pancreatic cancer: risk-adapted dose prescription and image-guided delivery.
Mazzola R; Fersino S; Aiello D; Gregucci F; Tebano U; Corradini S; Di Paola G; Cirillo M; Tondulli L; Ruffo G; Ruggieri R; Alongi F
Strahlenther Onkol; 2018 Sep; 194(9):835-842. PubMed ID: 29696321
[TBL] [Abstract][Full Text] [Related]
4. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
6. SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.
Tozzi A; Comito T; Alongi F; Navarria P; Iftode C; Mancosu P; Reggiori G; Clerici E; Rimassa L; Zerbi A; Fogliata A; Cozzi L; Tomatis S; Scorsetti M
Radiat Oncol; 2013 Jun; 8():148. PubMed ID: 23799996
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
8. Higher Biologically Effective Dose Predicts Survival in SBRT of Pancreatic Cancer: A Multicentric Analysis (PAULA-1).
Arcelli A; Guido A; Buwenge M; Simoni N; Mazzarotto R; Macchia G; Deodato F; Cilla S; Bonomo P; Scotti V; Belgioia L; Tolento G; Cellini F; Grassi E; DI Marco M; Casadei R; Morganti AG; Cammelli S
Anticancer Res; 2020 Jan; 40(1):465-472. PubMed ID: 31892602
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Chemotherapy Alone Versus Radiotherapy-Based Regimens in Locally Advanced Pancreatic Cancer: A Real-World Multicenter Analysis (PAULA-1).
Arcelli A; Tarantino G; Cellini F; Buwenge M; Macchia G; Bertini F; Guido A; Deodato F; Cilla S; Scotti V; Rosetto ME; Djan I; Parisi S; Mattiucci GC; Fiore M; Bonomo P; Belgioia L; Niespolo RM; Gabriele P; Di Marco M; Simoni N; Ma J; Strigari L; Mazzarotto R; Morganti AG
Curr Oncol; 2023 Jun; 30(6):5690-5703. PubMed ID: 37366910
[TBL] [Abstract][Full Text] [Related]
12. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
14. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
[TBL] [Abstract][Full Text] [Related]
15. Stereotactic body radiation therapy for locally advanced pancreatic cancer.
Jung J; Yoon SM; Park JH; Seo DW; Lee SS; Kim MH; Lee SK; Park DH; Song TJ; Ryoo BY; Chang HM; Kim KP; Yoo C; Jeong JH; Kim SC; Hwang DW; Lee JH; Song KB; Jo YY; Park J; Kim JH
PLoS One; 2019; 14(4):e0214970. PubMed ID: 30978229
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Reirradiation with Stereotactic Body Radiation Therapy for Locally Recurrent Pancreatic Adenocarcinoma.
Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK
Clin Oncol (R Coll Radiol); 2022 Jun; 34(6):386-394. PubMed ID: 34974972
[TBL] [Abstract][Full Text] [Related]
17. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience.
Moningi S; Dholakia AS; Raman SP; Blackford A; Cameron JL; Le DT; De Jesus-Acosta AM; Hacker-Prietz A; Rosati LM; Assadi RK; Dipasquale S; Pawlik TM; Zheng L; Weiss MJ; Laheru DA; Wolfgang CL; Herman JM
Ann Surg Oncol; 2015 Jul; 22(7):2352-8. PubMed ID: 25564157
[TBL] [Abstract][Full Text] [Related]
18. Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer.
Lin JC; Jen YM; Li MH; Chao HL; Tsai JT
Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):259-64. PubMed ID: 25629569
[TBL] [Abstract][Full Text] [Related]
19. Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study.
Comito T; Cozzi L; Clerici E; Franzese C; Tozzi A; Iftode C; Navarria P; D'Agostino G; Rimassa L; Carnaghi C; Personeni N; Tronconi MC; De Rose F; Franceschini D; Ascolese AM; Fogliata A; Tomatis S; Santoro A; Zerbi A; Scorsetti M
Technol Cancer Res Treat; 2017 Jun; 16(3):295-301. PubMed ID: 27311310
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
Park JJ; Hajj C; Reyngold M; Shi W; Zhang Z; Cuaron JJ; Crane CH; O'Reilly EM; Lowery MA; Yu KH; Goodman KA; Wu AJ
Acta Oncol; 2017 Dec; 56(12):1746-1753. PubMed ID: 28661823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
